Browsing Tag
KEYNOTE-942
1 post
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.